MAIA Biotechnology Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Vlad Vitoc

Chief Executive Officer (CEO)

US$1.4m

Compensación total

Porcentaje del salario del CEO	33.1%
Permanencia del CEO	no data
Participación del CEO	4.7%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Vlad Vitoc en comparación con los beneficios de MAIA Biotechnology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$26m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$1m	US$473k	-US$20m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$1m	US$443k	-US$16m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$703k	US$265k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Dec 31 2020	US$1m	US$75k	-US$7m

Compensación vs. Mercado: La compensación total de Vlad($USD1.43M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.63K).

Compensación vs. Ingresos: La compensación de Vlad ha aumentado mientras la empresa no es rentable.

CEO

Vlad Vitoc (54 yo)

no data

Permanencia

US$1,430,757

Compensación

Dr. Vlad Vitoc, MD., MBA., is the Co-founder, Chairman, President and Chief Executive Officer of MAIA Biotechnology, Inc. Dr. Vitoc is a well-seasoned biotech executive with a broad array of experience acr...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Vlad Vitoc	Co-Founder	no data	US$1.43m	4.67% $ 2.4m
Ngar Louie	Independent Director	4.6yrs	US$90.00k	4.87% $ 2.5m
Jerry Shay	Chairman of Scientific Advisory Board	3.2yrs	sin datos	sin datos
Steven Chaouki	Independent Director	3.2yrs	US$60.00k	0.46% $ 241.3k
Ramiro Guerrero	Independent Director	no data	US$60.00k	1.7% $ 887.2k
Cristian Luput	Independent Director	no data	US$60.00k	1.63% $ 846.6k
Stan Smith	Lead Independent Director	no data	US$75.00k	4.61% $ 2.4m
David Ashley	Member of Scientific Advisory Board	3.2yrs	sin datos	sin datos
Tudor Ciuleanu	Member of Scientific Advisory Board	3.2yrs	sin datos	sin datos
Z. Dikmen	Member of Scientific Advisory Board	3.2yrs	sin datos	sin datos
Adam Yopp	Member of Scientific Advisory Board	3.2yrs	sin datos	sin datos
Jean-Manasse Theagene	Independent Director	1.7yrs	US$47.50k	0% $ 0

3.2yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de MAIA se considera experimentada (3.2 años de antigüedad promedio).

MAIA Biotechnology Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

Lead Independent Director recently bought US$300k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology, Inc. announced that it expects to receive $2.439232 million in funding

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad